EA199900121A1 - Производные тетрагидрохинолина в качестве ингибиторов вак - Google Patents

Производные тетрагидрохинолина в качестве ингибиторов вак

Info

Publication number
EA199900121A1
EA199900121A1 EA199900121A EA199900121A EA199900121A1 EA 199900121 A1 EA199900121 A1 EA 199900121A1 EA 199900121 A EA199900121 A EA 199900121A EA 199900121 A EA199900121 A EA 199900121A EA 199900121 A1 EA199900121 A1 EA 199900121A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
alkoxy
alkyl
hydrogen
integer
Prior art date
Application number
EA199900121A
Other languages
English (en)
Other versions
EA001704B1 (ru
Inventor
Романо Ди-Фабио
Алессандра Паскуарелло
Фабио Мария Саббатини
Original Assignee
ГЛАКСО ВЕЛЛКАМ С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЛАКСО ВЕЛЛКАМ С.п.А. filed Critical ГЛАКСО ВЕЛЛКАМ С.п.А.
Publication of EA199900121A1 publication Critical patent/EA199900121A1/ru
Publication of EA001704B1 publication Critical patent/EA001704B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Соединения формулы (I)или их соль или метаболически лабильный эфир, где R представляет собой группу, выбранную из галогена, алкила, алкоксигруппы, аминогруппы, алкиламиногруппы, диалкиламиногруппы, гидроксигруппы, трифторметила, трифторметоксигруппы, нитрогруппы, цианогруппы, SORили COR, где Rпредставляет собой гидроксигруппу, метоксигруппу, аминогруппу, алкиламиногруппу или диалкиламиногруппу; m равно нулю или целому числу 1 либо 2; Rпредставляет собой группу (CH)CN, -СН=CHR, (СН)NHCOCHRили О(CH)NRR; Rпредставляет собой цианогруппу или группу COR; Rпредставляет собой алкоксигруппу или группу NHCOR; Rи Rкаждый независимо представляет собой водород или алкил, либо Rи Rвместе с атомом азота, к которому они присоединены, представляют собой гетероциклическую группу, либо Rявляется водородом, а Rявляется группой COR; Rпредставляет собой алкоксигруппу, аминогруппу или гидроксильную группу; Rпредставляет собой атом водорода или возможно замещенную алкильную, алкокси-, арильную или гетероциклическую группу; Rявляется группой Rили группой NRR, в которой Rпредставляет собой водород или алкильную группу; Rпредставляет собой возможно замещенную алкильную, арильную, гетероциклическую или циклоалкильную группу; n равняется нулю или целому числу от 1 до 4; р равняется целому числу от 2 до 4; способы их получения и их использование в медицине.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900121A 1996-08-17 1997-08-14 Производные тетрагидрохинолина в качестве антагонистов вак EA001704B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9617305.9A GB9617305D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds
PCT/EP1997/004440 WO1998007704A1 (en) 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives as eaa antagonists

Publications (2)

Publication Number Publication Date
EA199900121A1 true EA199900121A1 (ru) 1999-10-28
EA001704B1 EA001704B1 (ru) 2001-06-25

Family

ID=10798623

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900121A EA001704B1 (ru) 1996-08-17 1997-08-14 Производные тетрагидрохинолина в качестве антагонистов вак

Country Status (34)

Country Link
US (1) US6479488B1 (ru)
EP (1) EP0922034B1 (ru)
JP (1) JP4108129B2 (ru)
KR (1) KR100552864B1 (ru)
CN (1) CN1131214C (ru)
AP (1) AP877A (ru)
AR (1) AR008296A1 (ru)
AT (1) ATE221052T1 (ru)
AU (1) AU724473B2 (ru)
BR (1) BR9711311B1 (ru)
CA (1) CA2264118C (ru)
CO (1) CO4900066A1 (ru)
CZ (1) CZ296250B6 (ru)
DE (1) DE69714265T2 (ru)
DK (1) DK0922034T3 (ru)
EA (1) EA001704B1 (ru)
ES (1) ES2181030T3 (ru)
GB (1) GB9617305D0 (ru)
HU (1) HU225797B1 (ru)
ID (1) ID18095A (ru)
IL (1) IL128141A0 (ru)
IS (1) IS4953A (ru)
MY (1) MY116952A (ru)
NO (1) NO312241B1 (ru)
NZ (1) NZ333812A (ru)
PE (1) PE107098A1 (ru)
PL (1) PL194532B1 (ru)
PT (1) PT922034E (ru)
SI (1) SI0922034T1 (ru)
TR (1) TR199900336T2 (ru)
TW (1) TW449582B (ru)
WO (1) WO1998007704A1 (ru)
YU (1) YU6799A (ru)
ZA (1) ZA977326B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
CN100402032C (zh) * 2001-12-28 2008-07-16 阿卡蒂亚药品公司 用作毒蕈碱激动剂的四氢喹啉类似物
BRPI0406592A (pt) * 2003-01-23 2005-12-20 Acadia Pharm Inc Usos de n-desmetilclozapina, métodos para o tratamento de psicose, de distúrbios afetivos, de demência, de dor neuropática e de glaucoma e composição farmacêutica
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20060233843A1 (en) * 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
US7550454B2 (en) * 2003-12-22 2009-06-23 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
JP2007536216A (ja) * 2004-04-01 2007-12-13 アカディア ファーマシューティカルズ，インコーポレーテッド 固体ｎ−デスメチルクロザピンおよびその結晶形を合成および単離する方法
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
BRPI0613771B1 (pt) * 2005-07-22 2021-11-23 Mochida Pharmaceutical Co., Ltd Composto derivado de heterociclideno acetamida, composição farmacêutica e antagonista de receptor de tipo i vaniloide com potencial de receptor transitório (trpv1)
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
EP2324838A1 (en) * 2005-09-12 2011-05-25 Abela Pharmaceuticals, Inc. Compositions Comprising Dimethyl Sulfoxide (DMSO)
US7955418B2 (en) 2005-09-12 2011-06-07 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated with same
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
US9855212B2 (en) 2009-10-30 2018-01-02 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases
CA2850707C (en) 2011-10-03 2023-03-21 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL93610A0 (en) 1989-03-08 1990-12-23 Merck Sharp & Dohme Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them
WO1997012870A1 (en) * 1995-09-29 1997-04-10 Glaxo Wellcome S.P.A. Tetrahydroquinolines as nmda antagonists

Also Published As

Publication number Publication date
CZ52999A3 (cs) 1999-07-14
IS4953A (is) 1999-01-22
CN1131214C (zh) 2003-12-17
DE69714265D1 (de) 2002-08-29
PL331562A1 (en) 1999-07-19
EP0922034A1 (en) 1999-06-16
NO990723L (no) 1999-04-14
KR100552864B1 (ko) 2006-02-20
MY116952A (en) 2004-04-30
JP2001508031A (ja) 2001-06-19
US6479488B1 (en) 2002-11-12
PE107098A1 (es) 1999-01-15
TR199900336T2 (xx) 1999-04-21
ATE221052T1 (de) 2002-08-15
NO312241B1 (no) 2002-04-15
PL194532B1 (pl) 2007-06-29
AP877A (en) 2000-09-27
AU4551897A (en) 1998-03-06
CZ296250B6 (cs) 2006-02-15
CA2264118A1 (en) 1998-02-26
ZA977326B (en) 1999-02-15
NZ333812A (en) 2000-07-28
WO1998007704A1 (en) 1998-02-26
AR008296A1 (es) 1999-12-29
DK0922034T3 (da) 2002-11-18
EP0922034B1 (en) 2002-07-24
AP9901459A0 (en) 1999-03-31
CA2264118C (en) 2008-06-17
BR9711311B1 (pt) 2009-01-13
HUP9903108A3 (en) 2004-04-28
GB9617305D0 (en) 1996-09-25
KR20000068172A (ko) 2000-11-25
NO990723D0 (no) 1999-02-16
SI0922034T1 (en) 2003-02-28
HU225797B1 (en) 2007-09-28
ID18095A (id) 1998-02-26
ES2181030T3 (es) 2003-02-16
TW449582B (en) 2001-08-11
CO4900066A1 (es) 2000-03-27
EA001704B1 (ru) 2001-06-25
JP4108129B2 (ja) 2008-06-25
DE69714265T2 (de) 2003-03-06
PT922034E (pt) 2002-12-31
BR9711311A (pt) 1999-08-17
CN1227544A (zh) 1999-09-01
IL128141A0 (en) 1999-11-30
YU6799A (sh) 2000-03-21
AU724473B2 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
EA199900121A1 (ru) Производные тетрагидрохинолина в качестве ингибиторов вак
RU92004336A (ru) Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты
ES487537A0 (es) Un procedimiento para la preparacion de nuevos derivados de quinazolina.
RU94045915A (ru) Производные индола, способ их получения, фармкомпозиция
HUP9902459A2 (hu) Szubsztituált indazolszármazékok és felhasználásuk IV-típusú foszfodiészteráz (PDE) aktivitásának, és a tumornekrózis-faktor (TNF) keletkezésének gátlására
DK0464465T3 (da) Substituerede aminoalkylbiphenylderivater, antimykotiske præparater indeholdende disse derivater og mellemprodukter til fremstilling deraf
YU59601A (sh) Derivati piridopiranoazepina, njihovo pripremanje i terapeutska primena
DE69511260T2 (de) Bicyclische amidinderivate als no-synthetase inhibitoren
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
ATE56006T1 (de) Succinimide derivate, herstellung und anwendung.
ES536402A0 (es) Un procedimiento para la preparacion de nuevos derivados de quinazolina e isoquinolina.
NO890440L (no) Fremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater.
PL290676A1 (en) Method of obtaining novel derivatives of 2-aminoalkyl-5-diaryl-alkyl-1.3-dioxane
EA200001165A1 (ru) Производные тетрагидрохинолина в качестве антагонистов глицина
FR2631827B1 (fr) Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique
NO961404L (no) 4-indolylpiperazinyl-derivater
GB0116966D0 (en) Anittumoral compounds
EA200200352A1 (ru) Фенил- и пиридил-тетрагидропиридины, обладающие ингибирующей активностью в отношении фактора некроза опухоли (фно)
NO883387L (no) Fremgangsmaate for fremstilling av 2'-deoksy-5-fluoruridinderivater.
EA200200462A1 (ru) Производные 2-арилхинолина, их получение и терапевтическое применение
EP0192992A3 (en) Quinoxaline derivatives useful for treatment and prophilaxis of swine dysentery and as animal growth promotants

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU